Mineralys Therapeutics: A Story To Keep An Eye On [Seeking Alpha]
Mineralys Therapeutics, Inc. (MLYS)
Company Research
Source: Seeking Alpha
The company's sole asset, lorundrostat, is an aldosterone synthase inhibitor that has shown promising results in Phase 2 trials for the treatment of uncontrolled hypertension. Mineralys is conducting two additional trials for lorundrostat and is also evaluating its potential for the treatment of hypertension in patients with chronic kidney disease. A full investment analysis follows in the paragraphs below. Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » Today, we put hypertension concern Mineralys Therapeutics, Inc. ( NASDAQ: MLYS in the spotlight. The stock is off slightly since its public debut in February of 2023, owing to a lack of market moving news regarding its sole asset lorundrostat, but that could change beginning in 2H24. With three readouts coming over the next two years, but some clinical rivals to surmount, the insider buying on the recent private placement merited a d
Show less
Read more
Impact Snapshot
Event Time:
MLYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLYS alerts
High impacting Mineralys Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MLYS
News
- Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024GlobeNewswire
- Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $30.00 price target on the stock.MarketBeat
- Mineralys Therapeutics, Inc. (NASDAQ: MLYS) had its "outperform" rating re-affirmed by analysts at Lifesci Capital.MarketBeat
- Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
MLYS
Earnings
- 3/21/24 - Beat
MLYS
Sec Filings
- 4/15/24 - Form 4
- 4/12/24 - Form EFFECT
- 4/11/24 - Form 424B5
- MLYS's page on the SEC website